CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Intra‑Articular Hyaluronan Injections for Osteoarthritis

This policy governs coverage for intra-articular hyaluronan (viscosupplementation) injections for osteoarthritis for Blue Cross & Blue Shield of Rhode Island Commercial products and describes coding and medical necessity stance.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyIntra‑Articular Hyaluronan Injections for Osteoarthritis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 1, 2016

Next Review DateN/A

Key ActionDo not submit claims for intra‑articular hyaluronan J‑codes for Commercial products as they are considered not medically necessary; providers may request individual case review by submitting clinical information to the Individual Consideration Unit.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CommercialApplies to

Not medically necessaryCoverage stance

14 J‑codesHCPCS impacted

20610, 20611CPT impacted

Apr 16, 2020Last updated

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Intra‑articular Hyaluronan Injections

Not Medically Necessary / Insufficient Evidence

Covered when ALL of the following are met:

Commercial products coverage stance: Intra-articular hyaluronan injections of the knee and all other joints are considered not medically necessary as the evidence is insufficient to determine the effects on health outcomes.

Policy cites mixed randomized controlled trial and meta-analysis evidence with concerns about bias, small‑trial effects, and lack of clinically meaningful benefit for knee osteoarthritis; evidence for other joints is insufficient.

Policy summary: For Commercial Products, intra‑articular hyaluronan (viscosupplementation) injections of the knee and all other joints are considered not medically necessary. The evidence is insufficient to determine the effects of this technology on health outcomes. Specific HCPCS J‑codes for hyaluronan products are listed as not medically necessary, and the CPT procedure codes 20610 and 20611 are not medically necessary when billed in conjunction with one of the listed HCPCS codes.

Scope and details: This policy applies to hyaluronan injections administered intra‑articularly for osteoarthritis of the knee and for any other joint when provided to members under Commercial Products. The policy enumerates specific HCPCS codes for hyaluronan and derivatives (for example, J7318, J7320, J7321, J7322, J7323, J7324, J7325, J7326, J7327, J7328, J7329, J7331, J7332) that are considered not medically necessary. Additionally, when one of the listed HCPCS codes is billed, the associated CPT codes for arthrocentesis/injection of a major joint or bursa (20610 and 20611) are also considered not medically necessary.

Coding — HCPCS and CPT Codes

Not Covered HCPCS CodesHCPCSNot Covered

J7318	Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg
J7320	Hyaluronan or derivative, GenVisc 850, for articular injection, 1 mg
J7321	Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose
J7322	Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg
J7323	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
J7324	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
J7325	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg
J7326	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
J7327	Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose
J7328	Hyaluronan or derivative, Gel-syn, for intra-articular injection, 0.1 mg

1–10 of 13

1/2

Not Covered CPT Codes when used with listed HCPCSCPTNot Covered

20610	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa)
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance, with permanent recording and reporting

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Not applicable

Note

Medical Criteria

Not applicable

Note

Individual Consideration

All of our medical policies are written for the majority of people with a given condition. Each policy is based on medical science. For many of our medical policies, each individual's unique clinical circumstances may be considered in light of current scientific literature. Physicians may send relevant clinical information for individual patients for consideration to:

Individual Consideration Unit of Basic Claims Administration, Blue Cross & Blue Shield of Rhode Island, 500 Exchange Street, Providence, RI 02903-2699
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable network and benefit information.

Background

Background: Knee osteoarthritis (OA) is a common and disabling condition for which there is no curative therapy; treatment goals focus on reducing pain, improving function, and delaying surgery. Intra‑articular hyaluronan (viscosupplementation) is intended to restore synovial fluid viscoelasticity and to reduce OA symptoms, but most clinical evidence—primarily randomized trials and meta‑analyses for knee OA—has produced mixed results with concerns about bias and limited clinically meaningful benefit. Because the available evidence does not clearly demonstrate improved health outcomes, use of IA hyaluronan for the knee and other joints is judged not medically necessary for Commercial Products.

Definitions

Viscosupplementation / Intra-articular hyaluronan (IAHA) — definition and intended effect

TermViscosupplementation / Intra-articular hyaluronan (IAHA)

DefinitionInjection of hyaluronan into a joint to replace endogenous hyaluronan and restore the viscoelastic properties of synovial fluid; may include cross-linked hyaluronan (hylans).

Intended effectRestore synovial fluid viscoelasticity to reduce pain and improve joint function in osteoarthritis, primarily studied in the knee.

Typical targetsKnee osteoarthritis (primary approved indication); other joints (eg, hip, shoulder) have been investigated but evidence is limited.

Mechanism noteHyaluronan is a naturally occurring macromolecule in synovial fluid; cross-linking increases molecular weight (hylans).

Revision History

2016-02-01policy_effective

Policy effective date: coverage stance established that intra-articular hyaluronan injections for the knee and other joints are considered not medically necessary for Commercial Products.

2020-04-16last_reviewLatest

Policy last reviewed and retained coverage stance as not medically necessary for intra-articular hyaluronan injections for Commercial Products.

Billing Rule

Billing/Coding — HCPCS (J‑codes)

Use of the listed HCPCS (J‑codes) for hyaluronan or derivatives is considered not medically necessary for Commercial Products and may trigger denial.

J7318 — Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg (effective 1/1/2019)
J7320 — Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
J7321 — Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose
J7322 — Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg
J7323 — Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
J7324 — Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
J7325 — Hyaluronan or derivative, Synvisc or Synvisc‑One, for intra-articular injection, 1 mg
J7326 — Hyaluronan or derivative, Gel‑One, for intra-articular injection, per dose
J7327 — Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose
J7328 — Hyaluronan or derivative, Gel‑syn, for intra-articular injection, 0.1 mg
J7329 — Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg (effective 1/1/2019)
J7331 — Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg (effective 10/1/2019)
J7332 — Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg (effective 10/1/2019)